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Plants have been a source of medicines in human cultures for millennia. The past
decade has seen a decline in plant-derived medicines due to the time-consuming
nature of screening for biological activity and a narrow focus on individual candidate
plant taxa. A phylogenetically informed approach can be both more comprehensive in
taxonomic scope and more systematic, because it allows identification of evolutionary
lineages with higher incidence of medicinal activity. For these reasons, phylogenetics
is being increasingly applied to the identification of novel botanic sources of medicinal
compounds. These biologically active compounds are normally derived from plant
secondary or specialized metabolites generally produced as induced responses and
often playing a crucial role in plant defense against herbivores and pathogens. Since
these compounds are typically bioactive they serendipitously offer potential therapeutic
properties for humans, resulting in their use by traditional societies and ultimately drug
lead development by natural product chemists and pharmacologists. The expression
of these metabolites is likely the result of coevolutionary processes between plants
and the other species with which they interact and effective metabolites are thus
selected upon through evolution. Recent research on plant phylogeny coupled with
metabolomics, which is the comprehensive analysis of metabolite profiles, has identified
that related taxa produce similar secondary metabolites, although correlations are
dependent also on environmental factors. Modern mass spectrometry and bioinformatic
chemical networking tools can now assist high throughput screening to discover
structurally related and potentially new bioactive compounds. The combination of these
metabolomic approaches with phylogenetic comparative analysis of the expression of
metabolites across plant taxa could therefore greatly increase our capacity to identify
taxa for medicinal potential. This review examines the current status of identification
of new plant sources of medicine and the current limitations of identifying plants as
drug candidates. It investigates how ethnobotanic knowledge, phylogenetics and novel
approaches in metabolomics can be partnered to help in characterizing taxa with
medicinal potential.
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PLANTS AS A SOURCE OF MEDICINE
Plants have been a perennial source of human therapeutics. The
use of plants for medicine has been documented as early as
2600 BC (Gurib-Fakim, 2006) and plants still play a major role
in treating human diseases. People in developing countries rely
heavily on plant-derived traditional medicines (De Luca et al.,
2012), accounting for close to 80% of world population (Gurib-
Fakim, 2006). In the United States, a considerable proportion of
approved drugs are derived from plants (9.1% according to the
USFDA; United States Food and Drug Administration (Newman
and Cragg, 2016). Furthermore, there are many drugs that are
modified analogs of plant derived secondary metabolites that
are in wide use (e.g., aspirin derived from the natural product
salicin, from the willow tree Salix alba L., codeine and morphine
from the opium poppy Papaver somniferum L.) (Dias et al.,
2012). There are over 28,000 medicinal plants recorded in the
scientific literature (Allkin, 2017) that are based on knowledge
from traditional medicine.
Despite the prevalence of plants in traditional medicine, the
majority of plant taxa have not received formal experimental
appraisal for their medicinal properties. During the early twenty-
first century there has actually been a decline in the use of plants
as a source of medicine in the pharmaceutical industry (Atanasov
et al., 2015). Of the plant species recorded as having therapeutic
properties, only 16% have been tested for biological activity
(Willis, 2017). Furthermore, the pharmaceutical industry more
commonly uses synthetic chemistry for drug design, even though
success in finding new leads are limited (Li and Vederas, 2009)
and there is a vast diversity of plants with biological activity that
could be drug candidates. This decline is a result of the challenges
faced in the conventional plant-based drug discovery process
which make the overall process time consuming (Figure 1). The
process starts with identifying the species of plant known to
have medicinal function, sourcing the plant material, obtaining
approval according to international legislations such as the
convention on biological diversity and the Nagoya protocol on
access to genetic resources, isolating the bioactive compound
or compounds, identification of it, and ultimately synthesizing
the candidate compound (Liu and Wang, 2008; Atanasov et al.,
2015). For example, in the case of the drug artesunate derived
from artemisinin originally discovered from Artemisia annua
L., used to treat malaria, there was an 18 month lag between
initial identification and production of the candidate drug.
The time delay was due to the 6 month Artemisia cultivation
period followed by the bioactive compound purification period
(Wells et al., 2015). This was prior to the longer process of
bioassaying, and before clinical testing. In addition to these
practical issues, identifying the biologically active compounds
from the plant source is challenging due to the enormous
chemical diversity of plants and possibility of synergistic effects
among compounds (Kingston, 2011). Furthermore, elucidating
the mechanism of action of plant-based drugs also remains a
slow process. These are only the delays after a plant source
has been identified, and do not consider the time taken to
identify that original botanic source in the first place. Overall this
process of screening plant taxa for biological activity is costly,
so the pharmaceutical industry tends to opt for other sources
for medicines.
The study of therapeutic traditional use of plants is a
multidisciplinary area, because both pharmacology of the plant
and human behavior has affected whether and how the plant
is used. As an example in traditional medicine there are many
instances where complex herbal mixtures are used (Leonti and
Casu, 2013). In such instances the metabolites in the herbal
mixture may need to act in synergy to yield the pharmacological
effects (Wagner, 2011). Further, some plant-based traditional
medicines may also have different preparation methods. Based
on the preparation methods the mode of action of the medicinal
metabolites may differ (Heinrich et al., 2009). In addition
to that some traditional communities may also select plants
based on specific traits (De Medeiros et al., 2015). Therefore,
consideration should be given to all of these related processes
in ethnopharmacological studies. Despite these complications,
ethnopharmacology still does provide a credible starting point in
narrowing the target taxa for natural product chemistry research.
There are also significant challenges for managing how
ethnopharmacological knowledge is partnered with scientific
discovery methods and the pharmaceutical industry. Cultural
appropriation and exploitation of traditional knowledge is a
serious and ongoing issue given that intellectual property is
often regulated by researchers and pharmaceutical companies
(Mcgonigle, 2016). Thus a mechanism to acknowledge the
indigenous knowledge of ethnobotany also needs to be adopted
in drug discovery (Gupta et al., 2005). The International Platform
on Biodiversity and Ecosystem Services (IPBES) established
in 2012, acknowledges by developing and governing a set
of principles that recognizes the contribution and knowledge
of indigenous and local cultures in the use of biodiversity
(Pert et al., 2015). Thus, the use of a proper legal framework
and collaborations of indigenous communities, scientist and
policymakers may also greatly help in sharing and utilizing the
wealth of ethnopharmacological knowledge (Shane, 2004).
Largely in the pharmaceutical industry, drug discovery
novelties are few and the need for bioactive compounds are
persisting. Given the lengthy process of sampling, screening
and biological testing, many plants are not investigated. Despite
evidence that plants are a rich source of bioactive compounds.
Hence the need for alternative approaches, to identify plants in
a systematic manner for their medicinal potential is required.
Novel approaches for identifying medicinal plant taxa more
effectively need to be explored (Liu and Wang, 2008).
Recent advancements in the screening processes for natural
products are stimulating renewed effort in plant-based drug
discovery. Most notably, the 2015 Nobel Prize for medicine
was awarded for identifying an antimalarial compound from
Artemisia annua L. using the knowledge of traditional Chinese
medicine (Tu, 2011). Currently the two main drugs used
to treat malaria are plant derived (artemisinin and quinine
from Cinchona L. barks) highlighting that plant-derived
pharmaceuticals are highly relevant for drug discovery.
Furthermore, during the last decade, several new plant-derived
drugs (apomorphine hydrochloride; water lily (Nymphaea L. sp),
galanthamine hydrobromide; snowdrop (Galanthus nivalis L.),
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FIGURE 1 | Conventional pathway from random screening to novel drugs, using Taxus brevifolia Nutt. and alternative partially synthetic pathway from Taxus baccata
L. as example species, a process which took over 30 years (based on information from Wani et al., 1971; Holton et al., 1994; Wall and Wani, 1995; Baloglu and
Kingston, 1999; Liu and Wang, 2008; Weaver, 2014).
nitisinone; bottlebrush plant (Callistemon citrinus Curtis.),
tiotropium bromide; devil’s snare (Datura stramonium L.)
and Cytisine; golden rain acacia (Cytisus laborinum L.) have
been approved by the USFDA (Das, 2017; Auffret et al., 2018).
According to World Bank projections, a growth rate of 5–15%
annually in the plant-based medicinal market is anticipated (Liu
and Wang, 2008). Thus, identifying biologically active potential
medicinal plant sources is currently a commercially viable and
beneficial research area, albeit one with significant cultural issues.
ROLE OF PLANT
SECONDARY/SPECIALIZED
METABOLITES IN TREATING DISEASES
A medicinal plant is defined as a botanical source able to cure,
prevent or relieve a disease, or a plant that is utilized as a drug or a
precursor for a drug (Rates, 2001). Most of the active components
of newly developed drugs are plant secondary metabolites
(Balunas and Kinghorn, 2005). Plant secondary metabolites are
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compounds that are not directly responsible for plant growth
and development, instead they are the products of specific sets
of enzymatic reactions broadly known as metabolic reactions
(Hartmann, 2007). Many plant secondary metabolites serve as
defensive compounds produced to overcome the challenges
plants face in the environment, including pathogens and
herbivores but also abiotic stressors (Wink, 1988). In addition,
some of these secondary metabolites also serve as allelopathic
defensive compounds, synthesized in response to competition
from surrounding plants (Reigosa and Pazos-Malvido, 2007).
These chemical entities are specialized/secondary metabolites,
which are typically expressed systemically, but occasionally the
expression of these secondary metabolites is localized.
Plant secondary metabolites are structurally specialized
by having highly active functional groups (i.e., aldehyde,
sulfhydryl groups, epoxides, hydroxyl, and carbonyl groups)
to act on cellular targets, such as enzymes, cell receptors
and transporters. Therefore, when a medicinal plant product
is ingested by humans, the secondary metabolites mediate
a chain of reactions that may be beneficial in treating
diseases (Acamovic and Brooker, 2005; Wink, 2015). As
a result of their effect on the biological systems of hosts,
secondary metabolites exhibit major properties as for example
antiviral, antimicrobial, antifungal, antimalarial, analgesic,
antiarrhythmic, antihypertensive, psychoactive, and tumor
inhibition agents. However, out of c.100,000 known bioactive
secondary metabolites, remarkably few have been scientifically
screened for their activity (Wink, 2015).
The biggest challenge is identifying the target bioactive
compound from the plant material, since every crude plant
extract contains thousands of compounds, most of which
are unknown (Atanasov et al., 2015). Thus, identification of
biologically active compounds is done through comparing the
chemical structures of compounds identified from the plant, to
those already existing in compound libraries typically used in
analytical processes (i.e., mass spectrometry (MS) and nuclear
magnetic spectroscopy (NMR) (Dias et al., 2016). Examples of
these include KNApSAcK (Afendi et al., 2012), the Universal
Natural Product Database (UNDP) which is an open source
library with bioactivity information, the Global Natural Product
Database (GNPS) and Massbank (Johnson and Lange, 2015).
However, these libraries do not include all the natural products
that plants produce (Schwager et al., 2008). Furthermore,
inevitably if searching for new candidate drugs, many plant
compounds are likely to be new to science (Takeuchi et al., 2018),
and hence not present in compound libraries. Therefore, studies
providing broad identification of the secondary metabolites with
biological activity from plants, can provide an enormous amount
of information applicable to the discovery of new therapeutic
plants (Harvey et al., 2015).
IDENTIFYING THERAPEUTIC PLANTS
ACROSS THE PLANT KINGDOM
Known medicinal activity is not randomly distributed across
the plant kingdom. There are specific distribution patterns
where certain lineages are significantly more bioactive (Coley
et al., 2003). This pattern is also reflected in the traditional
use of plants by humans. Different cultures around the world
tend to use related plant taxa for similar medicinal purposes
(Saslis-Lagoudakis et al., 2011). This ethnobotanical convergence
suggests that therapeutic potential may have phylogenetic
constraints (Zhu et al., 2011 Kowiyou et al., 2015; Garnatje
et al., 2017). Therefore, by investigating ethnopharmacological
use of plants, phylogenetically related target species for further
investigation could be identified.
Phylogenetic exploration of approved drugs of natural origin
has identified 11 major plant clades that have delivered the
significant part of these approved drugs (Zhu et al., 2011).
Likewise, there is evidence of particular plant lineages expressing
specific secondary metabolites with medicinal function (Rønsted
et al., 2012). For example, in-depth studies of the synthesis
of the secondary metabolites of terpene structure reveal that
there are seven groups of gene families responsible for terpene
synthesis. These genes are specific to plant lineages (land plants,
vascular plants, gymnosperms) and the types of terpenes they
synthesize varies, respectively between clades (Feng et al., 2011).
Thus, a broader understanding of how the genes responsible for
secondarymetabolism have evolved across plant taxa will provide
information on the type of secondary metabolites synthesized by
a plant lineage.
Secondary metabolites can be either ubiquitous or expressed
in specific plant lineages (Chezem and Clay, 2016). Since
secondary metabolites confer survival benefits to plants, they
are under natural selection (Wink, 2003). The genes responsible
for plant secondary metabolism are versatile and have high
plasticity to adapt to environmental pressures. In contrast, the
genes responsible for primary metabolism are stringent and
expression is generally relatively inflexible (Hartmann, 2007).
Genes responsible for secondary metabolism therefore have the
ability to be upregulated and downregulated across lineages
in response to selection imposed by the other species with
which they interact (e.g., herbivorous insects) or environmental
stress factors. This presents extra challenges to drug discovery
as environmental factors can also play a role in the amount
of a particular bioactive compound present in a natural
product extract.
Differential gene expression is responsible for the
lineage specificity of secondary metabolites. For example,
in Arabidopsis thaliana (L.) Heynh. and other closely related
Brassicaceae plants, glucosinolate expression is controlled
by the methylthioalkylmalate (MAM) synthases gene cluster
(Benderoth et al., 2006). Studies of differential expression of
MAM genes have shown that positive natural selection has
shaped the synthesis of glucosinolates as a defense mechanism to
insect herbivory (Benderoth et al., 2006; Figueiredo et al., 2008).
The phylogenetic history of Arabidopsis and its close relatives
reveals specific gene duplication points, where new MAM genes
were positively selected for the combinations of glucosinolates
that those genes encoded (Benderoth et al., 2006). Synthesis of
many plant secondary metabolites is regulated by different gene
families, and they could have similar underlying gene duplication
and selection histories explaining their diversity.
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Differential gene expression in secondary metabolism is
also driven by coevolution—the correlated evolution between
two groups of ecologically interacting organisms, resulting
in reciprocal evolution of both groups in response to each
other (Ehrlich and Raven, 1964). Coevolution-mediated
expression of secondary metabolites has been a major hypothesis
in understanding the differential expression of secondary
metabolites across plant lineages (Speed et al., 2015). One of
the best studied models of coevolution concerns the chemical
diversity of the family Apiaceae (which includes such well-
known plants as dill; Anethum graveolens L., coriander;
Coriandrum sativum L., cumin; Cuminum cyminum L. and
fennel; Foeniculum vulgare Mill.). The coevolution of the
Apiaceae and Papilio butterflies is reflected in their shared
patterns of phylogeny where chemical shifts in the phylogeny
of the butterflies has governed host plant diversifications
(Berenbaum, 2001; Berenbaum and Zangerl, 2008). Several other
well-documented examples of reciprocal adaptations between
host plants and their specialist herbivores include Barbarea
vulgaris (Aiton) (rocketcress; Brassicaceae) and Phyllotreta
nemorum L. (turnip flea beetle), Brassicales plants and Pierinae
butterflies, and Pastinaca sativa L. (Parsnips; Apiaceae) and
Depressaria pastinacella (Duponchel) (Parsnip webworm)
(Zangerl et al., 2003; Toju and Sota, 2006; Agrawal et al., 2012b;
Edger et al., 2015).
Plant secondary metabolite expression can also be driven by
generalized, rather than specialized, herbivores. Recent research
on Amazonian trees (from the tribe Protieae; Burseraceae)
showed that secondary metabolites able to act as herbivore
repellents were found frequently in high abundances in Protieae
tribe plants, even in the absence of specialized herbivores.
This suggests that regardless of the type of herbivore, the
mere existence of any natural enemy can affect how secondary
metabolites are expressed in plants (Salazar et al., 2018).
Conversely, Oenothera biennis L. (common evening-primrose)
populations grown in controlled insect pest-free environments,
had reduced defenses against insects pests over time, i.e., they
reduced their production of toxic secondary metabolite in
response to decreased herbivory (Agrawal et al., 2012a).
Some of the chemical drivers behind the expression of
these secondary metabolites are herbivore-associated elicitors
(metabolites released into the plant by the herbivores). Many
of these elicitors are produced by insects, and range from
enzymes and modified lipids to sulfur containing fatty acids
(Bonaventure et al., 2011). These elicitors have the ability
to stimulate biosynthetic pathways within a plant (Waterman
et al., 2019). Further, the action of these elicitors tends to be
associated with certain plant-insect associations. For example
the lepidopteran Manduca sexta L. (tobacco hornworm) releases
fatty acid-amino acid conjugates into the plant that stimulate
the biosynthesis of jasmonic acid in Nicotiana attenuata Torr. ex
S.Watson (wild tobacco) (Wu et al., 2007; Meldau et al., 2011).
Jasmonic acid afterwards mediates the synthesis of secondary
metabolites as defense compounds in N. attenuata (Kallenbach
et al., 2010). Thus, expression of secondary metabolites is
governed both by evolution (i.e., one-way adaptation in response
to generalized herbivory) and coevolution (i.e., specific reciprocal
adaptation between the interacting host and a herbivore species)
(Caseys et al., 2015).
Overall, the genetic mediation of plant secondary metabolite
expression does not act in isolation. There are abiotic factors
such as temperature, soil pH, and frost exposure that may
have effects on overall plant secondary metabolism. In Zea
mays L. (corn) changes in abiotic factors as soil humidity,
temperature and light had significant effects on the volatile
secondary metabolite production (Gouinguen and Turlings,
2002). These environmental stresses are also correlated with the
abundance of natural enemies or herbivores and plant pathogens
which themselves affect the expression of secondary metabolites
(Müller and Orians, 2018). Therefore, studying secondary
metabolite expression, in the light of coevolution would provide
a more holistic and biologically relevant method to understand
differential gene expression, and thus the distribution and
occurrence of plant secondary metabolites. This has theoretical
implications for the tracking the expression of traits according to
phylogeny, as well as for medicinal and drug discovery.
USE OF PHYLOGENY AND
METABOLOMICS TO IDENTIFY
BIOLOGICAL ACTIVITY IN PLANTS
Understanding how secondary metabolite gene expression varies
across clades is a potential key to identifying biologically
active plants. For example, the kinds of enzyme-encoding gene
clusters used by algae and mosses are distinctively different
from those found in grasses and eudicots (Chae et al., 2014).
Furthermore, analysis of the metabolomic reactions within these
plant groups has shown that closely-related taxa express the
same set of reactions, thus suggesting phylogenetic constraints
on secondary metabolite expression. If true, in depth analysis
of plant secondary metabolite evolution would help us to
understand which taxa/clades are biologically active, and hence
are good candidates as medicinal species. In other words, the
phylogenetic patterns of secondary metabolite expression could
potentially act as a marker for biological activity, and therefore
potential medicinal use.
There have been numerous studies in the past decade
describing phylogenetic patterns of secondary metabolite
expression. Analysis of volatile terpenes from angiosperm taxa
has shown phylogenetically conserved expression, with related
species producing the same terpenoid across the phylogeny.
In particular, species belonging to the Magnoliid clade such as
orders Laurales, Magnoliales had very high terpene diversity
(Courtois et al., 2016). This suggests that the origin of the
Magnoliids 122–125 million years ago is a key evolutionary point
at which plant volatile terpene synthesis increased significantly.
TheMagnoliids are also one of the eleven clades predicted to have
significantly higher pharmacological activity (Zhu et al., 2011).
Indeed, over a quarter (18 families) of the 66 drug productive
families identified, are from the Magnoliid clade (Zhu et al.,
2011). Other lineages with high degrees of bioactivity are mosses
from the order Hypnales, conifers (Pinales, was Coniferales),
plus angiosperms from the monocots (Commelinids, and orders
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FIGURE 2 | (A) Hypothetical molecular network for three compounds eluting at different retention times, with different parent masses (left, indicated from the MS
parental ion spectra in yellow, blue, and magenta)—but with similar MS/MS fragment ion spectra, right (A), (B), and (C). The similarity score is calculated for the
MS/MS fragmentation patterns based on number of peaks that are similar across (A–C). 1 is a single peak difference between (A) and (B) (highlighted in green)—the
similarity score of yellow and blue MS/MS fragment spectra is 0.9. 2 a single peak difference between (B) and (C) (highlighted in green)—the similarity score of blue
and magenta MS/MS fragment spectra is also 0.9. 1 and 2 combined are two peaks difference between (A) and (C)—the similarity score of yellow and magenta
MS/MS fragment spectra is therefore somewhat less = 0.8. The molecular network is generated by calculating the similarity score between yellow, blue, and magenta
compounds (parent ions- the nodes in the network) based on the MS/MS fragmentation (C), (B), and (A). The connecting lines (edges) gives the similarity score.
Threshold values of similarity can be set to determine presence within a network.
Asparagales and Liliales), the basal or early diverging eudicots
(Ranunculales) and more derived eudicots (Fabids and Malvids
from the Rosids, and Lamiids and Campanuliids from the
Asterids) (Zhu et al., 2011); APG IV 2016). Phylogenetic patterns
in bioactivity (through secondary metabolite expression)
have also been examined at the genus level for the angiosperms
Euphorbia (Euphorbiacae; Rosid) andNarcissus (Amaryllidaceae;
Asparagales) with both genera yielding significant phylogenetic
signals in biologically active secondary metabolite expression
(Rønsted et al., 2008; Ernst et al., 2016).
The strong patterns of phylogenetically conserved expression
of secondary metabolites could underlie the observed
ethnobotanical convergence, in which similar plant taxa are
used in similar ways in different parts of the world. Research on
cross cultural patterns of medicinal plant usage reports the use
of taxa from the same clades, across continents to treat similar
diseases, signifying that there is phylogenetically non-random
selection of therapeutic plants by indigenous cultures (Saslis-
Lagoudakis et al., 2011, 2012). As an example, there are accounts
for using Piper umbellatum L. (cow foot leaf; Piperaceae,
Magnoliid) to treat kidney and digestive diseases across North
America, Africa and South East Asia (Roersch, 2010). Further
cross-cultural patterns have been revealed in a larger study
across a number of genera e.g., Aloe Aloe vera (L.) Burm. f.
(Asphodelaceae; Asparagales), the breadfruit Artocarpus altilis
(Parkinson) Fosberg (Moraceae; Rosid), Papaw Carica papaya
L. (Caricaceae; Brassicales) and love vine Cassytha filiformis L.
(Lauraceae, Magnoliid) used for medicinal preparations across
the Caribbean Islands (Halberstein, 2005). Thus, information
from traditional medicine, along with biological activemetabolite
expression, coupled with phylogeny could be the strategy for
next generation drug productive taxa identification.
Recent research has used phylogenetic approaches to predict
medicinal potential of plants. For example, phylogenetic
mapping was performed for plant species with compounds used
for treating cardiovascular disease, based on ethnobotanic and
pharmacological mode of action of the drug. Seven angiosperm
plant families were identified as having similar pharmacology:
Zingiberaceae (Commelinid monocot), Brassicaceae, Fabaceae,
Malvaceae, Rosaceae (Rosids), and Apiaceae and Lamiaceae
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FIGURE 3 | Proposed integrated approach for identifying potentially medicinal plant taxa using metabolomics profiles of species A, B, C, and D (phylogenetically
closely related species belonging to same operational taxonomic unit/family) and species P, Q, and R (likewise but from a different operational taxonomic unit/family).
(A) Hypothetical secondary metabolites identified using UHPLC-MSMS in respect to taxa A, B, C, D, P, and Q. Only taxa A and Q have previously known traditional
medicinal uses. Taxa A and Q express the already identified bioactive metabolites X and Y, respectively. Taxon D is phylogenetically closely related to taxa A, B, and C.
It does not have any known medicinal properties or identified bioactive metabolites. Taxon R is phylogenetically closely related to taxa P and Q. It does not have
known medicinal properties or identified bioactive metabolites. (B) Hypothetical GNPS based molecular network* and the molecular phylogeny of the corresponding
taxa. Potentially medicinal taxa. These taxa could be identified by looking at the molecular network cluster patters and the phylogenetic relationships of the target
taxa D and R for which there are no previous records of metabolomic profiles. Given that their respective locations in relation to taxa A, B, C, P, and Q, statistical
inferences could be used to predict the medicinal potential based on phylogeny and metabolomic features. *In the molecular network the nodes are further divided in
to pie charts to represent the taxa sharing a particular metabolite. The area corresponds to the parent ion intensities in each node produced by respective taxa. The
color code of the nodes correspond to the color code on the metabolites table and the phylogeny for ease of understanding the figure.
(Asteriids). Those families have been suggested as potential
target clades for identifying novel leads in treating cardiovascular
diseases (Guzman and Molina, 2018). Despite these promising
advances, research to date has not specifically quantified the
capacity of phylogeny to predict medicinal potential in specific
lineages. This can be done by measuring the phylogenetic signal
of a trait (Münkemüller et al., 2012), in this case, biological
activity, across a large clade of plants with a high frequency of
reported traditional medicinal use.
Phylogenetic signal reflects the tendency of closely-related
species to be phenotypically similar in contrast to species drawn
at random from the same phylogeny (Blomberg et al., 2003).
It can be measured via a number of metrics for data that
are continuous (quantitative) or discrete (e.g., presence/absence
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data) (Fritz and Purvis, 2010; Münkemüller et al., 2012;
Kamilar and Cooper, 2013). In a medicinal use context, Fritz
and Purvis’s (2010) D statistic has been used to compare
the phylogenetic distribution of presence/absence of both
therapeutic use and expression of particular compounds across
plant species, and whether this conforms to either a random
distribution (with no phylogenetic signal) or distribution that
would be expected if the trait had evolved by Brownian
motion (gradual divergent evolution) (Saslis-Lagoudakis et al.,
2015). This has been used to identify a phylogenetic signal of
medicinal potential in the family Amaryllidaceae in relation
to alkaloid diversity, where five of seven alkaloid groups
exhibited weak, but significant, phylogenetic signal (Rønsted
et al., 2012). The D statistic was also used to map the
phylogenetic signal in leaf succulence and medicinal use across
the genus Aloe finding that a succulent leaf habit is associated
with the potential of a species to be used as a medicine
(Grace et al., 2015). Furthermore, the D statistic has also
been used to predict presence of artemisinin and antimalarial
properties in other Artemisia (other than Artemisia annua
L. (Pellicer et al., 2018).
USING PHYLOGENETIC TRAIT MAPPING
AND MOLECULAR NETWORKING TO
PREDICT MEDICINAL POTENTIAL
Novel techniques of metabolomics such as molecular networking
can be used to identify metabolites that are structurally
similar to already known bioactive metabolites (Allard et al.,
2016). In molecular networking the fragmentation pattern of a
metabolite (Tandem mass spectrometry-MS/MS fragmentation)
is compared with other compounds and similar metabolites
are identified based on the structure (Figure 2). These are
then put into network clusters, where a single cluster would
therefore refer to a single metabolite group that likely share many
similar chemical (and hence potentially bioactive) properties.
Therefore, this technique allows one to identify groups of
potentially bioactive metabolites, and novel compounds with
such properties. Further, by treating such networks as phenotypic
characters, one can map their expression onto phylogenies and
identify clades with related bioactive properties in a way that does
not rely specifically on the identification of single compounds.
Tandem mass spectrometry-MS/MS based molecular
networking has been extremely informative in chemical
similarity studies identifying related chemical entities across
taxa/clades. Once the chemical entities are identified using
Global Natural Product Social Molecular Networking (GNPS),
it is possible to identify which taxa share the same molecular
network cluster. Furthermore, MS/MS spectra can be related to
biosynthetic pathways and their biological activity using online
databases for natural products, thus providing information on
the medicinal potential of a taxon. One limitation with this
approach is that it requires some pre-existing knowledge of
chemical compounds’ biological activity to identify analogs with
similar potential. It may not be so effective in identifying novel
biologically active compounds that have completely undescribed
chemical composition.
There have been numerous studies identifying novel bioactive
candidate compounds using molecular networking in species
such as in the Euphorbiacaee species Euphorbia dendroides
L. (tree spurge) and Codiaeum peltatum (Labill.) P.S.Green
(croton), and identifying chemicals of cannabinomimetic activity
from the cyanobacteria genus Moorea (Kleigrewe et al., 2015;
Nothias et al., 2018; Olivon et al., 2018). However, the focus
of these studies was on single taxa without considering their
evolutionary history. Multi-species studies do exist, as in the
recent study of acetylcholinesterase inhibitors produced by a
range of Iranianmonocot and eudicot flowering plant taxa, where
new compounds as well as taxa responsible for expressing the new
compounds were identified (Abbas-Mohammadi et al., 2018), but
again the study taxa here were restricted only to knownmedicinal
species, with little consideration of phylogenetic relatedness
except in few recent research concerning Euphorbiaceae (Ernst
et al., 2018). However, with the existence of phylogenetic and
metabolomic information across multiple species, this approach
could be further scaled up to comprising taxa with ethnobotanic
medicinal use as well as their sister taxa for which no known
records of ethnobotanical medicinal use exist, to identify target
taxa for medicinal potential (see Figure 3).
In summary, the combination of ethnobotanic information,
phylogeny and molecular networking provides a promising
approach to plant natural product-based drug discovery. By
investigating the metabolomics profiles, of a target highly
bioactive plant clade comprising both known medicinal and
understudied taxa, chemically related taxa could be identified via
molecular networking. The phylogenetic signal of those chemical
compounds (or chemical networks) could be quantitatively
measured by constructing the phylogeny and using phylogenetic
signal-measuring statistical methods. This will allow prediction
of the medicinal potential of previously understudied taxa.
Combining these approaches holds a key to the advancement of
plant derived natural product drug discovery.
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